Organisation paid for research Program year 2025 Source: CMS Open Payments

Digestive Disease Specialists Inc

Neither a doctor nor a teaching hospital

Research payments

$1,190,650

298 payments

Through program year 2025, Digestive Disease Specialists Inc is reported as receiving $1,190,650 in research payments, across 298 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$77,570	24
2024	Research	$60,958	29
2023	Research	$322,651	50
2022	Research	$30,183	12
2021	Research	$24,926	15
2020	Research	$307,163	100
2019	Research	$367,200	68

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $360,126 90 payments
Genentech, Inc. $272,823 40 payments
Janssen Research & Development, LLC $144,260 31 payments
Takeda Pharmaceuticals U.S.A., Inc. $143,106 44 payments
Allergan Inc. $103,982 26 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $72,134 8 payments
Arena Pharmaceuticals, Inc. $41,253 3 payments
Boehringer Ingelheim RCV GmbH & Co KG $27,382 47 payments
Pfizer Inc. $13,009 4 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $10,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Roche Cancer Screening Collection Study $272,823 40 payments
Oral Budesonide Suspension (Obs) in Adolescents and Adult Subjects With Eosinophilic Esophagitis: DB, Maintenance $98,738 23 payments
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease $88,939 14 payments
M14-675 $56,364 5 payments
M14-234 $49,978 7 payments
M14-431 $40,270 9 payments
A Phase 2 Randomized Doubleblind Placebocontrolled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis $39,333 1 payment
M16-006 $39,314 10 payments
Phase 2 longterm Open Label Extension Study in UC $33,938 4 payments
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $32,834 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.